SPRINT-TB: Shaping Biosciences in Singapore 2025

Clearstate, the Economist Intelligence Unit, interviewed SPRINT-TB Director Prof. Nicholas Paton and SPRINT-TB Manager Dr. Kristina Rutkute for their views in a white paper on Singapore's biosciences landscape in 2025. The paper was commissioned by BioSingapore, a trade association representing life sciences companies in Singapore.
​
The white paper gathers perspectives from a wide range of industry and research participants, influencers and key opinion leaders on what lies ahead for Singapore's biosciences industry. It examines trends shaping the sector, weighs Singapore's standing against regional clusters, and considers how the country should build industry capabilities going forward. The publication offers themes that can help guide the development of fresh ideas to drive the next phase of biosciences growth in Singapore. 

You can download the white paper here.

We congratulate Dr. Gail Cross, a Clinical Research Fellow with SPRINT-TB Theme 3, on winning the September 2015 Pitch for Funds Round with a project titled "Evaluating Whole Blood Bactericidal Activity of Bortezomib against Mycobacterium tuberculosis in Healthy Volunteers". The SGD $10,000 award will support a clinical study that tests bortezomib (a compound identified by Theme 1 as effective against Mtb) in a whole blood bactericidal activity assay.

'Pitch for Funds' is an event run by the NUHS Clinician Scientist Unit to support registrars and associate consultants who carry out interdisciplinary research with collaborators from the National University of Singapore Yong Loo Lin School of Medicine. Each competitive pitch round, held twice a year, sees two outstanding presentations chosen by a review panel receive the funding award.